Matches in Wikidata for { <http://www.wikidata.org/entity/Q64816891> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q64816891 description "assaig clínic" @default.
- Q64816891 description "clinical trial" @default.
- Q64816891 description "clinical trial" @default.
- Q64816891 description "clinical trial" @default.
- Q64816891 description "clinical trial" @default.
- Q64816891 description "ensaio clínico" @default.
- Q64816891 description "ensayo clínico" @default.
- Q64816891 description "ensayu clínicu" @default.
- Q64816891 description "essai clinique" @default.
- Q64816891 description "klinisch onderzoek" @default.
- Q64816891 description "клінічне випробування" @default.
- Q64816891 name "Plinabulin vs. Pegfilgrastim in Reducing the Duration of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)" @default.
- Q64816891 type Item @default.
- Q64816891 label "Plinabulin vs. Pegfilgrastim in Reducing the Duration of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)" @default.
- Q64816891 prefLabel "Plinabulin vs. Pegfilgrastim in Reducing the Duration of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)" @default.
- Q64816891 P1050 Q64816891-D8CFCB3C-6169-4D01-864E-DEF8681D550A @default.
- Q64816891 P1132 Q64816891-FDF3CD29-CC60-4C47-8FDE-F5D61DB81225 @default.
- Q64816891 P1476 Q64816891-674B33F5-5C47-47FF-A976-84B1C2C1D5F4 @default.
- Q64816891 P17 Q64816891-DC4774C0-1B37-4460-AECD-E19E8EDDCDE1 @default.
- Q64816891 P2899 Q64816891-89DADF4C-B1A5-4827-B462-D3B44420B7A7 @default.
- Q64816891 P3098 Q64816891-164AD6BA-672B-4BD9-9C23-2F553BE03584 @default.
- Q64816891 P31 Q64816891-826F6E2D-F3F3-4DE2-B4D8-602862163FB2 @default.
- Q64816891 P4844 Q64816891-22C91A0C-52AC-4DAC-B705-D467C4311867 @default.
- Q64816891 P4844 Q64816891-4FD0CC87-787C-469B-99FD-7C25F4F0B640 @default.
- Q64816891 P4844 Q64816891-A7A9B1CB-63CC-4C0B-8943-BE48E645A50A @default.
- Q64816891 P580 Q64816891-3325F363-50DB-4A55-974A-B7067FF89FCE @default.
- Q64816891 P582 Q64816891-37FD72F4-AD35-4F0B-BD0A-B8CFE312F623 @default.
- Q64816891 P6099 Q64816891-AA9EBA7A-FDF0-4BF3-9F1A-C14AA938BFD9 @default.
- Q64816891 P6099 Q64816891-B9EE9DE5-B0D7-4F98-ABC3-6BF542983A0A @default.
- Q64816891 P8363 Q64816891-6AB70251-3A70-47AB-A39E-5A450181A3DD @default.
- Q64816891 P921 Q64816891-BEB5E842-1FA4-4860-8BAC-20FB6DE829FA @default.
- Q64816891 P1050 Q1435822 @default.
- Q64816891 P1132 "+237" @default.
- Q64816891 P1476 "A Phase 2/3, Multicenter, Randomized Study to Evaluate Plinabulin Versus Pegfilgrastim in Reducing the Duration of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) (Protective 2)" @default.
- Q64816891 P17 Q212 @default.
- Q64816891 P2899 "+18" @default.
- Q64816891 P3098 "NCT03294577" @default.
- Q64816891 P31 Q30612 @default.
- Q64816891 P4844 Q18936 @default.
- Q64816891 P4844 Q29004943 @default.
- Q64816891 P4844 Q408524 @default.
- Q64816891 P580 "2017-11-27T00:00:00Z" @default.
- Q64816891 P582 "2020-01-15T00:00:00Z" @default.
- Q64816891 P6099 Q42824440 @default.
- Q64816891 P6099 Q42824827 @default.
- Q64816891 P8363 Q78089383 @default.
- Q64816891 P921 Q1592932 @default.